Conflixis is a technology company.
Conflixis has raised $4.0M across 1 funding round.
Conflixis has raised $4.0M in total across 1 funding round.
Conflixis has raised $4.0M in total across 1 funding round.
Conflixis's investors include F-Prime Capital Partners, Lerer Hippeau, NextView Ventures, Origin Ventures.
Conflixis is a healthcare technology startup building an AI-powered platform for managing conflicts of interest (COI) in healthcare compliance. It automates disclosure collection, review, risk scoring, reporting, and resolution, integrating provider-submitted data, external sources like Open Payments, procurement records, claims data, and behavioral signals to surface actionable insights faster and more accurately than manual processes.[1][2][3][4] Serving hospitals, medical practices, research institutions, and compliance teams, Conflixis solves the problem of opaque financial entanglements—such as undisclosed relationships with drug/device makers—that undermine trust, inflate costs (e.g., 20% of hospital budgets on conflicted suppliers), evade detection (70% undisclosed), and trigger fines (over $2.2B in 2024).[1][3][4] Early growth includes replacing manual workflows in hours, saving up to 4 hours per provider disclosure and 2 hours per relationship review, amid rising payer scrutiny and regulatory demands.[3]
Conflixis was founded by Aaron Narva (CEO) and Joseph Bergen (co-founder and engineering lead), drawing from Narva's extensive background in risk management and investigations. Narva previously worked as an incident investigator at firms like Kroll and FTI Consulting, then at compliance software company Exiger, where he monitored a major bank's post-money-laundering compliance and used AI tools for corruption detection in unstructured data.[4] This experience highlighted parallels between financial sector risks and healthcare COI, where drug/device companies' ties to doctors (e.g., fees, junkets, grants) mirror banking scandals but lack robust tools.[1][4] Narva pitched the idea to childhood friend Bergen, then director of engineering at BuzzFeed; Bergen quit to co-found Conflixis.[4] The team, blending enterprise risk, AI/data engineering, and compliance expertise, built the platform after analyzing kickback settlements, disclosure datasets, and form-based system flaws—realizing the need for signal-rich automation over more paperwork.[1]
Conflixis rides the AI-compliance wave in healthcare, where exploding data volumes (e.g., Open Payments) and scandals amplify COI risks amid private equity ownership and payer scrutiny for medical necessity.[1][3][4] Timing is ideal post-2024's $2.2B fines and correlations between industry ties/higher costs, as regulators demand transparency in a system strained by "do more with less."[1][3] Market tailwinds include AI's maturity for unstructured data analysis and healthcare's shift to automation, reducing 50%+ undisclosed relationships among providers.[3] It influences the ecosystem by enabling accountable innovation—cutting waste, shielding reputations, and paving financial relationships that benefit patients—positioning COI management as core infrastructure, not an add-on.[1]
Conflixis is primed for expansion as AI refines risk signals and integrations deepen with HR/supplier systems, potentially capturing share in a fragmented compliance market.[3][4] Trends like stricter payer audits, AI ethics in healthtech, and post-fine regulatory pushes will accelerate adoption, evolving its role from workflow replacer to ecosystem standard.[1][3] Influence may grow via partnerships with hospitals facing procurement pressures, ultimately making COI a trust enabler rather than a shadow over healthcare progress—equipping teams to lead accountably, as its founders envisioned from risk fronts to clinic frontlines.[1][4]
Conflixis has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2024 | $4.0M Seed | F-Prime Capital Partners, Lerer Hippeau, NextView Ventures, Origin Ventures |